[ARDX] Ardelyx, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.6 Change: 1.2 (8.96%)
Ext. hours: Change: 0 (0%)

chart ARDX

Refresh chart

Strongest Trends Summary For ARDX

ARDX is in the long-term down -86% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 an

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -35.61% Sales Growth - Q/Q-7.19% P/E-1.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.46% ROE-6.28% ROI
Current Ratio5.12 Quick Ratio Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-15.85% Net Profit Margin-12.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-1.05 M Cash From Operating Activities-8.21 M Gross Profit
Net Profit-3.5 M Operating Profit-3.49 M Total Assets105.4 M Total Current Assets101.91 M
Total Current Liabilities19.91 M Total Debt Total Liabilities47.4 M Total Revenue5.88 M
Technical Data
High 52 week7.9 Low 52 week1.66 Last close2.23 Last change-4.29%
RSI69.29 Average true range0.19 Beta1.5 Volume61.04 K
Simple moving average 20 days10.4% Simple moving average 50 days-8.8% Simple moving average 200 days-41.66%
Performance Data
Performance Week-7.08% Performance Month3.72% Performance Quart-39.89% Performance Half-52.04%
Performance Year-68.59% Performance Year-to-date24.58% Volatility daily5.5% Volatility weekly12.3%
Volatility monthly25.21% Volatility yearly87.35% Relative Volume187.64% Average Volume352.07 K
New High New Low

News

2019-09-13 12:29:27 | A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019

2019-09-13 11:08:03 | Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

2019-09-13 08:24:12 | Ardelyx ARDX in Focus: Stock Moves 8.3% Higher

2019-09-13 07:40:02 | The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

2019-09-12 15:12:00 | Ardelyx Receives FDA Approval for IBSRELA® Tenapanor, an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

2019-09-12 07:38:39 | The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study

2019-09-11 17:47:02 | East Bay company eyes first drug approval after decade-long journey

2019-09-04 16:42:04 | Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

2019-09-04 12:07:41 | A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

2019-09-04 12:00:00 | Why Ardelyx Shares Are Sinking Today

2019-09-04 10:31:02 | Ardelyx ARDX Gains on Tenapanor's Success in Pivotal Study

2019-09-04 10:02:02 | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

2019-09-04 07:08:03 | The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

2019-09-03 10:56:00 | Why Ardelyx Is Soaring Today

2019-09-03 08:00:00 | Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

2019-09-02 16:00:00 | Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

2019-08-21 13:06:52 | How Many Ardelyx, Inc. NASDAQ:ARDX Shares Do Institutions Own?

2019-08-19 06:00:00 | 5 Biggest New Drug Approvals Potentially on the Way in 2019

2019-08-09 09:25:01 | Ardelyx ARDX Reports Q2 Loss, Misses Revenue Estimates

2019-08-09 08:00:00 | Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights

2019-07-30 10:38:02 | Ardelyx ARDX May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-07-09 13:49:01 | Does The Ardelyx, Inc. NASDAQ:ARDX Share Price Tend To Follow The Market?

2019-06-25 20:33:43 | Is Ardelyx Inc ARDX A Good Stock To Buy?

2019-05-30 09:00:00 | Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-16 12:56:15 | Why Ardelyx, Inc.'s NASDAQ:ARDX CEO Pay Matters To You

2019-05-07 18:45:10 | Ardelyx ARDX Reports Q1 Loss, Misses Revenue Estimates

2019-05-07 17:34:27 | Ardelyx: 1Q Earnings Snapshot

2019-05-07 16:02:00 | Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights

2019-05-07 10:30:02 | Ardelyx ARDX Expected to Beat Earnings Estimates: Should You Buy?

2019-05-06 09:55:01 | What's in the Cards for Axon Enterprise AAXN Earnings?

2019-04-10 12:33:38 | If You Had Bought Ardelyx NASDAQ:ARDX Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today

2019-03-19 17:38:31 | East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?

2019-03-14 17:00:00 | Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors

2019-03-07 17:00:00 | Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

2019-03-06 16:05:00 | Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

2019-03-01 14:54:24 | An Examination Of Ardelyx, Inc. NASDAQ:ARDX

2019-02-21 08:00:00 | Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

2019-02-12 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

2019-02-07 06:30:00 | Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

2019-01-18 09:20:26 | Ardelyx, Inc. NASDAQ:ARDX Is Trading At A 28.78% Discount

2018-12-18 02:50:44 | Ardelyx Inc ARDX: Are Hedge Funds Right About This Stock?

2018-11-26 14:26:07 | What Type Of Shareholder Owns Ardelyx Inc’s NASDAQ:ARDX?

2018-11-13 08:30:00 | Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

2018-11-07 18:12:34 | Ardelyx: 3Q Earnings Snapshot

2018-11-07 16:05:00 | Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-10-26 13:01:00 | Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

2018-10-16 07:50:00 | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-10-08 08:01:00 | Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

2018-10-04 06:30:00 | Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

2018-09-18 08:19:01 | How Does Investing In Ardelyx Inc NASDAQ:ARDX Impact Your Portfolio?